Newsfeeds - Spark Newswire

1 minute read

News

Neurocrine Biosciences Announced Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning

By Charles Gross

Today, 1:00 PM

Neurocrine Biosciences, Inc.

NBIX

1 minute read

Evercore ISI Group Upgrades Neurocrine Biosciences to Outperform, Announces $130 Price Target

By Benzinga Newsdesk

Today, 1:00 PM

Evercore ISI Group analyst Joshua Schimmer upgrades Neurocrine Biosciences (NASDAQ:NBIX) from In-Line to Outperform and announces $130 price target.

NBIX

1 minute read

Mizuho Maintains Neutral on Neurocrine Biosciences, Maintains $116 Price Target

By Benzinga Newsdesk

Today, 1:00 PM

Mizuho analyst Uy Ear maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and maintains $116 price target.

NBIX

1 minute read

Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Lowers Price Target to $127

By Benzinga Newsdesk

Today, 1:00 PM

Cantor Fitzgerald analyst Charles Duncan reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $132 to $127.

NBIX

1 minute read

Barclays Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $131

By Benzinga Newsdesk

Today, 1:00 PM

Barclays analyst Carter Gould maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $136 to $131.

NBIX

1 minute read

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $140 Price Target

By Benzinga Newsdesk

Today, 1:00 PM

HC Wainwright & Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and maintains $140 price target.

NBIX

1 minute read

Neurocrine Biosciences Q4 Adjusted EPS $1.24 Beats $1.14 Estimate, Sales $412.00M Beat $409.09M Estimate

By Benzinga Newsdesk

Today, 1:00 PM

Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.14 by 8.77 percent. This is a 3000 percent increase over earnings of $0.04 per share

NBIX

1 minute read

Morgan Stanley Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $130

By Benzinga Newsdesk

Today, 1:00 PM

Morgan Stanley analyst Jeffrey Hung upgrades Neurocrine Biosciences (NASDAQ:NBIX) from Equal-Weight to Overweight and raises the price target from $120 to $130.

NBIX

2 minute read

Have A Look At William Blair’s Top Biotech Picks For 2023

By Vandana Singh

Today, 1:00 PM

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.

ALBO